Athanor Capital, LP Uni Qure N.V. Transaction History

Athanor Capital, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$29.24 - $42.03 $193,159 - $277,650	-6,606 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$35.35 - $50.67 $233,522 - $334,726	6,606 New	6,606 $239,000
Q3 2020 Nov 16, 2020	SELL	$35.98 - $47.66 $195,947 - $259,556	-5,446 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$45.06 - $67.74 $245,396 - $368,912	5,446 New	5,446 $245,000
Q1 2020 May 14, 2020	SELL	$40.01 - $73.97 $196,049 - $362,453	-4,900 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$37.13 - $74.62 $181,937 - $365,638	4,900 New	4,900 $351,000
Q2 2018 Aug 13, 2018	SELL	$21.96 - $39.94 $250,475 - $455,555	-11,406 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$17.1 - $26.61 $195,042 - $303,513	11,406 New	11,406 $268,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Athanor Capital, LP with notifications on news.